Kidder Stephen W Raises Stock Position in Eli Lilly and Company $LLY

Kidder Stephen W increased its stake in Eli Lilly and Company (NYSE:LLY) by 92.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,130 shares of the company’s stock after purchasing an additional 1,505 shares during the quarter. Kidder Stephen W’s holdings in Eli Lilly and Company were worth $2,440,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Secured Retirement Advisors LLC purchased a new stake in Eli Lilly and Company in the second quarter worth approximately $1,103,000. NBT Bank N A NY boosted its holdings in Eli Lilly and Company by 2.2% in the second quarter. NBT Bank N A NY now owns 10,648 shares of the company’s stock worth $8,300,000 after purchasing an additional 229 shares during the last quarter. Abel Hall LLC raised its position in Eli Lilly and Company by 26.0% in the second quarter. Abel Hall LLC now owns 1,121 shares of the company’s stock worth $874,000 after acquiring an additional 231 shares during the period. Somerville Kurt F raised its position in Eli Lilly and Company by 72.2% in the second quarter. Somerville Kurt F now owns 7,242 shares of the company’s stock worth $5,645,000 after acquiring an additional 3,036 shares during the period. Finally, Proffitt & Goodson Inc. raised its position in Eli Lilly and Company by 2,021.2% in the second quarter. Proffitt & Goodson Inc. now owns 700 shares of the company’s stock worth $546,000 after acquiring an additional 667 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. Berenberg Bank restated a “hold” rating and set a $830.00 price objective (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Cantor Fitzgerald cut their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. UBS Group cut their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $938.94.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Gabrielle Sulzberger purchased 117 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last quarter. 0.14% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Down 0.1%

Shares of Eli Lilly and Company stock opened at $844.30 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00. The firm has a market capitalization of $799.09 billion, a price-to-earnings ratio of 55.18, a PEG ratio of 1.18 and a beta of 0.47. The firm’s 50 day simple moving average is $736.97 and its two-hundred day simple moving average is $766.03.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.